On the other hand, breast cancer patients (n = 1100) with low CYP4B1 and CYP4F12 expression levels showed better cumulative survival, whereas patients with high CYP4F3 expression had better overall survival than their counterparts (Figure 7D). This evidence concerns the gene CYP4F3 and breast carcinoma.